title: Antibiotic prophylaxis for cesarean delivery: survey of maternal-fetal medicine physicians in the U.S.
abstract: OBJECTIVE
  To describe practices concerning antibiotic prophylaxis for cesarean delivery among maternal-fetal medicine (MFM) physicians in the United States.
  
  
  METHODS
  A 10-item self-administered survey about their routine use of antibiotics for cesarean delivery was mailed once only to a random sample of 1000 US-based fellows of the Society of Maternal-Fetal Medicine in November 2009.
  
  
  RESULTS
  There were a total of 250 respondents from 40 US states between 10/09 and 4/2010, corresponding to a response rate of 25%. Among respondents, 95.5% reported routine use of a cephalosporin only (including 84.4% who reported use of cefazolin) as antibiotic prophylaxis for cesarean delivery; less than 3% reported use of an extended spectrum regimen such as cefazolin + azithromycin. Preoperative administration of antibiotic prophylaxis was reported by 84.6% compared to 15.0% who reported giving antibiotic prophylaxis after umbilical cord clamping. Administration of a single dose of antibiotic was reported by 96%.
  
  
  CONCLUSIONS
  The majority of MFM specialists in the US report routine and preoperative use of a single prophylactic dose of a 1st generation cephalosporin for cesarean delivery.
authors.affiliation: Department of Obstetrics and Gynecology, Center for Women's Reproductive Health, University of Alabama at Birmingham, Birmingham, Alabama 35233, USA. amydoss625@gmail.com
authors.forename: Amy E
authors.initials: AE
authors.lastname: Doss
authors.forename: Jennifer D
authors.initials: JD
authors.lastname: Davidson
authors.forename: Suzanne P
authors.initials: SP
authors.lastname: Cliver
authors.forename: Luisa A L
authors.initials: LA
authors.lastname: Wetta
authors.forename: William W
authors.initials: WW
authors.lastname: Andrews
authors.forename: Alan T N
authors.initials: AT
authors.lastname: Tita
mesh_terms: D019072:Antibiotic Prophylaxis / Q000706:statistics & numerical data*; D017963:Azithromycin / Q000008:administration & dosage / Q000627:therapeutic use; D002437:Cefazolin / Q000008:administration & dosage / Q000627:therapeutic use; D002585:Cesarean Section / Q000534:rehabilitation / Q000706:statistics & numerical data*; D036861:Delivery, Obstetric / Q000706:statistics & numerical data; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D008297:Male; D008430:Maternal-Child Health Centers; D009774:Obstetrics / Q000379:methods / Q000706:statistics & numerical data; D010820:Physicians / Q000706:statistics & numerical data; D010818:Practice Patterns, Physicians' / Q000706:statistics & numerical data*; D011247:Pregnancy; D013530:Surgical Wound Infection / Q000453:epidemiology / Q000517:prevention & control*; D014481:United States / Q000453:epidemiology; D000078329:Workforce
chemical_list: D017963:Azithromycin; D002437:Cefazolin